OBJECTIVES: In Europe, meningococcal serogroup B is the most common cause of invasive meningococcal disease. The disease incidence is the highest among infants, young children and adolescents, while adolescents are considered the key transmitters of meningococci in the population. The disease is rare, but deadly and can cause permanent sequelae. The two new vaccines (4CMenB and rLP2086) were licensed in 2013 and 2017, respectively. Although the cost-effectiveness of vaccination with the vaccine 4CMenB has been assessed, only Ireland, Italy and England introduced this vaccine in the publicly funded national immunization programme (NIP), while Austria and the Czech Republic recommended it but without funding. The aim of the review is to summarise lessons learned from the cost-effectiveness studies and according to that contribute to decision-making for introducing the vaccine in the NIP in the remaining European countries. METHODS: : The databases of PubMed and NHS EED were searched systematically to identify contributions (up to April 15, 2018) on the cost-effectiveness of vaccination with the new vaccines versus no vaccination. Keywords like meningococcal, serogroup B, 4CMenB, rLP2086 and cost-effectiveness were used. The quality of these studies was assessed according to the CHEERS checklist, they were only in English, performed for European countries and included different age groups. The main characteristics of the included studies were extracted. RESULTS: A total of nine cost-effectiveness studies were analysed. According to these analyses, vaccination is likely not cost-effective due to low incidence of the disease. CONCLUSIONS: Infant vaccination is a relevant strategy to public health in the short run, while adolescent vaccination may be a more effective strategy in the long run, if herd effects are taken into account.